Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase 3 para avaliar o CYB003 no transtorno depressivo maior (EMBRACE)

12 de novembro de 2026 atualizado por: Cybin IRL Limited

Uma eficácia e segurança, Fase III, estudo multicêntrico, duplo-cego e randomizado, comparando 2 doses ativas de CyB003 e placebo em participantes elegíveis com transtorno depressivo maior

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

330

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Berlin, Alemanha, 10117
        • Ainda não está recrutando
        • Charité Universitaetsmedizin Berlin
        • Investigador principal:
          • Michael Koslowski
        • Contato:
      • Frankfurt am Main, Alemanha, 60528
        • Ainda não está recrutando
        • University Hospital Frankfurt
        • Investigador principal:
          • Andreas Reif
        • Contato:
      • Mannheim, Alemanha, 68159
        • Ainda não está recrutando
        • Central Institute of Mental Health
        • Contato:
        • Investigador principal:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Alemanha, 66421
        • Ainda não está recrutando
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Investigador principal:
          • Matthias Riemenschneider
        • Contato:
        • Contato:
    • New South Wales
      • Camperdown, New South Wales, Austrália, 2050
        • Recrutamento
        • Royal Prince Alfred Hospital
        • Investigador principal:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Austrália, 4558
        • Recrutamento
        • Thompson Brain & Mind Healthcare (TBMH)
        • Investigador principal:
          • Adem Can
        • Contato:
        • Contato:
    • Victoria
      • Melbourne, Victoria, Austrália, 3004
      • Melbourne, Victoria, Austrália, 3053
        • Recrutamento
        • Neurocentrix Research
        • Investigador principal:
          • David Barton
        • Contato:
        • Contato:
      • Notting Hill, Victoria, Austrália, 3168
        • Recrutamento
        • Monash University - Notting Hill
        • Contato:
        • Investigador principal:
          • Paul Liknaitzky
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35209
        • Recrutamento
        • UAB Psychiatry and Behavioral Neurology
        • Contato:
        • Investigador principal:
          • Peter Hendricks
        • Contato:
    • Arizona
      • Gilbert, Arizona, Estados Unidos, 85234
        • Recrutamento
        • Lighthouse Psychiatry
        • Contato:
        • Investigador principal:
          • Frank Genova
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72204
        • Retirado
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, Estados Unidos, 91206
        • Recrutamento
        • Behavioral Research Specialists, LLC
        • Investigador principal:
          • Jesse Carr
        • Contato:
      • Imperial, California, Estados Unidos, 92251
        • Retirado
        • Sun Valley Research Center
      • Los Angeles, California, Estados Unidos, 90025
        • Recrutamento
        • CalNeuro Research Group
        • Investigador principal:
          • Alexander Bystritsky
        • Contato:
      • Los Angeles, California, Estados Unidos, 90025
        • Recrutamento
        • Lipov Medical Group
        • Contato:
        • Investigador principal:
          • Jacob Moussai
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • NRC Research Institute
        • Contato:
        • Investigador principal:
          • Daniel Chueh
      • Orange, California, Estados Unidos, 92866
        • Recrutamento
        • ATP Clinical Research
        • Investigador principal:
          • Gustavo Alva
        • Contato:
      • San Juan Capistrano, California, Estados Unidos, 92675
        • Recrutamento
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Investigador principal:
          • Neelima Kunam
        • Contato:
      • Santa Monica, California, Estados Unidos, 90404
        • Recrutamento
        • Psychedelic Science Institute
        • Investigador principal:
          • Keith Heinzerling
        • Contato:
      • Stanford, California, Estados Unidos, 94305
        • Retirado
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06511
        • Recrutamento
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Investigador principal:
          • Ben Kelmendi
        • Contato:
          • Daidre Chamberlain
          • Número de telefone: 203-693-1591
          • E-mail: enact@yale.edu
        • Contato:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Recrutamento
        • CNS Healthcare
        • Contato:
          • Número de telefone: 904-281-5757
        • Investigador principal:
          • John Mark Joyce
      • Maitland, Florida, Estados Unidos, 32751
        • Recrutamento
        • Accel Research Sites - Maitland
        • Contato:
          • Número de telefone: 407-644-1165
        • Investigador principal:
          • Andrea Marrafino
      • Naples, Florida, Estados Unidos, 34105
        • Recrutamento
        • Aqualane Clinical Research
        • Investigador principal:
          • Matthew Baker
        • Contato:
      • Tampa, Florida, Estados Unidos, 33634
        • Recrutamento
        • K2 Medical Research Tampa
        • Investigador principal:
          • Kelley Wilson
        • Contato:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30329
        • Retirado
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, Estados Unidos, 30060
        • Recrutamento
        • Psych Atlanta
        • Investigador principal:
          • Michael Banov
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Recrutamento
        • Rush University
        • Investigador principal:
          • Joshua Eloge
        • Contato:
    • Louisiana
      • Marrero, Louisiana, Estados Unidos, 70006
        • Retirado
        • Tandem Clinical Research
      • New Orleans, Louisiana, Estados Unidos, 70115
        • Recrutamento
        • Atlas Psychiatry
        • Contato:
        • Investigador principal:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21224
        • Retirado
        • Johns Hopkins Medicine
      • Rockville, Maryland, Estados Unidos, 20850
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02116
        • Recrutamento
        • Adams Clinical Boston
        • Investigador principal:
          • Darin Dougherty
        • Contato:
      • Watertown, Massachusetts, Estados Unidos, 02472
        • Recrutamento
        • Adams Clinical Watertown
        • Investigador principal:
          • Stephanie Ellickson
        • Contato:
    • Minnesota
      • Eden Prairie, Minnesota, Estados Unidos, 55347
        • Recrutamento
        • Institute for Integrative Therapies
        • Investigador principal:
          • Manoj Doss
        • Contato:
      • Golden Valley, Minnesota, Estados Unidos, 55427
        • Ainda não está recrutando
        • The Remedy Mental Health
        • Contato:
        • Investigador principal:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89119
        • Recrutamento
        • Redbird Research, LLC
        • Investigador principal:
          • Jelena Kunovac
        • Contato:
    • New Jersey
      • Toms River, New Jersey, Estados Unidos, 08755
        • Recrutamento
        • Bio Behavioral Health
        • Contato:
        • Investigador principal:
          • Ashok Patel
    • New York
      • New York, New York, Estados Unidos, 10032
        • Ainda não está recrutando
        • New York State Psychiatric Institute
        • Investigador principal:
          • Natalie Gukasyan
        • Contato:
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Adams Clinical Harlem
        • Contato:
        • Investigador principal:
          • Wesley Gregory
      • The Bronx, New York, Estados Unidos, 10461
        • Recrutamento
        • Adams Clinical Bronx
        • Investigador principal:
          • Shama Farooq
        • Contato:
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73112
        • Retirado
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • Adams Clinical Philadelphia
        • Investigador principal:
          • Cassie Blanchard
        • Contato:
      • Philadelphia, Pennsylvania, Estados Unidos, 19462
        • Recrutamento
        • Flourish Research Philadelphia
        • Investigador principal:
          • Rachna Saralkar
        • Contato:
          • Número de telefone: 215-614-5606
    • Texas
      • Austin, Texas, Estados Unidos, 78737
        • Retirado
        • Austin Clinical Trial Partners
      • DeSoto, Texas, Estados Unidos, 75115
        • Recrutamento
        • Adams Clinical Dallas
        • Investigador principal:
          • Rajinder Shiwach
        • Contato:
      • Fort Worth, Texas, Estados Unidos, 76104
        • Retirado
        • North Texas Clinical Trials
      • Houston, Texas, Estados Unidos, 77046
        • Recrutamento
        • Brain Health Consultants and TMS Center
        • Investigador principal:
          • Lauren Marangell
        • Contato:
      • San Antonio, Texas, Estados Unidos, 78229
    • Washington
      • Everett, Washington, Estados Unidos, 98201
        • Ainda não está recrutando
        • Core Clinical Research
        • Contato:
        • Investigador principal:
          • James Knutson
      • Seattle, Washington, Estados Unidos, 98104
        • Recrutamento
        • Seattle Neuropsychiatric Treatment Center
        • Investigador principal:
          • Rebecca Allen
        • Contato:
      • Athens, Grécia, 12462
        • Recrutamento
        • Attikon University Hospital
        • Investigador principal:
          • Nikolaos Smyrnis
        • Contato:
      • Athens, Grécia, 11528
        • Recrutamento
        • Eginitio Hospital
        • Investigador principal:
          • Nikos Stefanis
        • Contato:
      • Thessaloniki, Grécia, 56404
        • Recrutamento
        • Papageorgiou General Hospital
        • Investigador principal:
          • Georgios Papazisis
        • Contato:
      • Dublin, Irlanda, D24 WK80
        • Recrutamento
        • Sheaf House - Tallaght Adult Mental Health Service
        • Investigador principal:
          • John Kelly
        • Contato:
      • Galway, Irlanda, H91 VE03
        • Recrutamento
        • La Nua Day Hospital Mental Health Centre
        • Contato:
        • Investigador principal:
          • Shane McInerney
      • Bialystok, Polônia, 15-272
        • Retirado
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Polônia, 85-133
        • Recrutamento
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Contato:
        • Investigador principal:
          • Katarzyna Lachut
      • Gdansk, Polônia, 80-546
        • Recrutamento
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Contato:
        • Investigador principal:
          • Hanna Badzio-Jagiello
      • Gdansk, Polônia, 80-214
        • Ainda não está recrutando
        • UCK
        • Investigador principal:
          • Wieslaw Jerzy Cubala
        • Contato:
      • Warsaw, Polônia, 02-957
        • Ainda não está recrutando
        • Department of Pharmacology and Physiology of CNS
        • Investigador principal:
          • Justyna Holka-Pokorska
      • Warsaw, Polônia, 02-172
        • Recrutamento
        • MTZ Clinical Research Powered by Pratia
        • Investigador principal:
          • Monika Gawlowicz
      • Cambridge, Reino Unido, CB1 2EU
        • Recrutamento
        • Cambridge University Hospital NHS
        • Investigador principal:
          • Liliana Galindo
        • Contato:
        • Contato:
      • Doncaster, Reino Unido, DN4 8QN
        • Recrutamento
        • Clerkenwell Health - Doncaster
        • Investigador principal:
          • Paul Morrison
        • Contato:
      • Edinburgh, Reino Unido, EH16 4TJ
        • Ainda não está recrutando
        • NHS Research Scotland
        • Investigador principal:
          • Donald MacIntyre
        • Contato:
      • Glasgow, Reino Unido, G51 4TF
        • Ainda não está recrutando
        • Queen Elizabeth University Hospital
        • Investigador principal:
          • Maytal Wolfe
        • Contato:
      • Liverpool, Reino Unido, L7 8XP
        • Ainda não está recrutando
        • Royal Liverpool Hospital
        • Contato:
        • Investigador principal:
          • Fabian Devlin
      • London, Reino Unido, EC2Y 8EA
        • Recrutamento
        • St Pancras Clinical Research
        • Investigador principal:
          • Martin Johnson
        • Contato:
      • London, Reino Unido, W1U 6RP
      • London, Reino Unido, W1G9 RU
        • Recrutamento
        • Re:Cognition Health
        • Investigador principal:
          • Dimitrios Paschos
        • Contato:
          • Número de telefone: +44-0800-802-1030
      • London, Reino Unido, SE5 9RS
      • London, Reino Unido, W1G 8DR
        • Retirado
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Reino Unido, NE4 5PL
      • Reading, Reino Unido, RG7 8PA
        • Recrutamento
        • Ascend Clinical Research
        • Investigador principal:
          • Pamela Walters
        • Contato:
      • Sheffield, Reino Unido, S4 7QQ
      • Prague, Tcheca
        • Ainda não está recrutando
        • Institute of neuropsychiatric Care (INEP)
        • Investigador principal:
          • Alexander Nawka
        • Contato:
          • Número de telefone: +420 222 201 020
          • E-mail: info@inep.cz
      • Prague, Tcheca
        • Ainda não está recrutando
        • Psyon s.r.o.
        • Investigador principal:
          • Tomas Palenicek
        • Contato:
      • Předměstí, Tcheca
        • Ainda não está recrutando
        • A-SHINE s.r.o.
        • Investigador principal:
          • Lubos Janu
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Experimental: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Comparador de Placebo: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Montgomery-Asberg Depression Scale (MADRS)
Prazo: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The Beck Depression Inventory - Second Edition (BDI-II)
Prazo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Prazo: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Prazo: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Prazo: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Felix Mazer, Cybin IRL Limited

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de dezembro de 2025

Conclusão Primária (Estimado)

7 de junho de 2027

Conclusão do estudo (Estimado)

9 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

21 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de janeiro de 2025

Primeira postagem (Real)

27 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CYB003-003

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .